In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Persistence of identical ECG pattern and prevalence of depolarization and repolarization markers in asymptomatic young individuals with incidentally found prominent J-wave over a period of 4 years.

Session Focus on early repolarisation

Speaker Eftihia Simeonidou

Event : EHRA 2015

  • Topic : arrhythmias and device therapy
  • Sub-topic : Arrhythmias, General
  • Session type : Moderated Posters

Authors : E Simeonidou (Athens,GR), C Michalakeas (Athens,GR), S Kastellanos (Athens,GR), C Varounis (Athens,GR), C Dai (Athens,GR), J Lekakis (Athens,GR)

Authors:
E. Simeonidou1 , C. Michalakeas1 , S. Kastellanos1 , C. Varounis1 , C. Dai1 , J. Lekakis1 , 12nd University Cardiology Dept, Attikon Hospital - Athens - Greece ,

Citation:
Europace Abstracts Supplement ( 2015 ) 17 ( Supplement 3 ), iii164

Purpose

The J-point elevation is a common electrocardiographic variant considered for years as benign ECG manifestation. Recently a high prevalence of this pattern was found in patients (pts) with idiopathic VF but the screening of subjects at risk for sudden cardiac death is difficult. Aim of the study was to evaluate the long-term evolution of the incidentally found ECG pattern of prominent J-wave and the prevalence of late potentials (LPs) testing (depolarization marker) and time domain T-wave alternans (TD-TWA) (repolarization marker) in healthy young individuals over a period of 4 years.

Methods

We studied 70 healthy young subjects (subjs) (13w, 57m) out of 77 of a previous study population, mean age 30±13 years, with incidental discovery of J-point elevation on the 12 lead ECG, who underwent 4 years ago LP testing by SAECG and time domain T-wave alternans (TD-TWA) by 24 hours Holter monitoring. They underwent annual clinical assessment, new ECG, SAECG and TD-TWA over a period of 4 years. Seventy consecutive healthy young subjs with normal ECG served as control population. All pts consented to LPs were considered positive when at least 2 criteria were met. The greater TD-TWA was chosen for assessment and it was defined as positive when the max voltage was >75 uV.

Results

In 4 years follow-up nobody developed any significant arrhythmias. The ECG localization of J-wave was initially in 15 subjs inferior, 40 anterior and 15 diffuse and remained identical without deterioration after 4 years. LPs were positive in 22 subjs (31%) and TD-TWA in 11 subjs (16%). Prevalence in healthy subjects with normal ECG is 4% and 3.2% respectively. Neither max TWA (p=0.751) nor LPs (p=0.493) were correlated to J- point ECG localization.

Conclusions

In our population of healthy young individuals with prominent J-point, the ECG pattern was not variable over time. The long-term prevalence of the depolarization marker LPs was significantly higher than in healthy subjects without prominent J-wave but it was not associated with any arrhythmic consequences in 4 years follow-up.

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are